MedTrace Logo

Safety Study of OPC-12759 Ophthalmic Solution

NCT01471093 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety of OPC-12759 ophthalmic solution in healthy subjects.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

OPC-12759 Ophthalmic solution

2％ OPC-12759 Ophthalmic solution

DRUG

OPC-12759 Ophthalmic suspension

2％ OPC-12759 Ophthalmic suspension

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eiji Murakami · Director of Division of Dermatologicals and Ophthalmologicals, Otsuka Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2011-12-31
Completion
2012-02-29

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471093 on ClinicalTrials.gov